Middle East and Africa accounts for 11.2% share of global clinical trial activity in 2020

26th February 2021 (Last Updated February 26th, 2021 15:00)

Middle East and Africa accounted for an 11.2% share of global clinical trials activity in 2020, a decrease of 0.5% compared with an 11.7% average over the last ten-years, according to GlobalData.

In Middle East and Africa, single country studies held an 85.2% share for all clinical trials in 2020, compared with the ten-year average of 80.0%. Multinational trials accounted for a 14.8% share in 2020 against an average of 20.0% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials in Middle East and Africa

Industry sponsored trials held a 23.5% share of all the clinical trials in Middle East and Africa in 2020, a drop over their ten-year average of 24.5%. Non-industry sponsored trials accounted for a 76.5% share in 2020, up from an average of 75.5% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 industry sponsored clinical trials in Middle East and Africa – Top therapy areas

Infectious Disease was the leading therapy area for industry sponsored clinical trials in Middle East and Africa in 2020 with a 37.8% share, up from its ten-year average of 17.8%.

Oncology held a 19.9% share in 2020, down from its ten-year average of 22.3%.

In the third place was Respiratory with an 11.7% share in 2020, up from its ten-year average of 6.5%. Central Nervous System recorded a 7.9% share in 2020, a drop over its ten-year average of 10.6%.

With a share of 6.7% in 2020, Gastrointestinal witnessed a drop over its ten-year average of 6.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-industry sponsored clinical trials in Middle East and Africa by top therapy areas

Infectious Disease was the leading therapy area for non-industry sponsored clinical trials in Middle East and Africa in 2020 with a 33.1% share, up from a ten-year average of 11.4%.

In the second place was Central Nervous System with a 25.1% share in 2020, which represented a drop over a ten-year average of 30.8%.

With a share of 9.0% in 2020, Respiratory witnessed a rise over its ten-year average of 3.6%. Women’s Health held an 8.2% share in 2020, as against ten-year average of 12.4%.

Gastrointestinal held a 5.8% share, which was down from ten-year average of 8.7%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

2020 clinical trials in Middle East and Africa by phase

In terms of phases, Phase III trials led the industry sponsored clinical trials in Middle East and Africa in 2020, with a share of 51.5%, marking a rise over a ten-year average of 51.2%.

Phase II trials stood next with a 28.2% share in 2020, which was down against a ten-year average of 30.2%.

In the third place was Phase I trials with a 12.4% share in 2020, up from its ten-year average of 7.5%.

Phase IV trials held an 7.9% share in 2020, with a 3.2% drop over its ten-year average of 11.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

For non-industry sponsored clinical trials in Middle East and Africa, Phase III trials held a leading share of 54.3% in 2020, up from its ten-year average of 33.8%.

In the second place was Phase II trials that held a 34.6% share in 2020 and saw an 18.3% drop over a ten-year average of 52.9%.

Phase IV trials stood at 7.3% share, as against ten-year average of 9.2%.

Phase I trials held a 3.8% share in 2020, down from its ten-year average of 4.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

 

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.